Stock Market News
Indivior files new lawsuit over Suboxone film
Indivior has filed patent lawsuits in the USA against five rivals for infringing a patent in their respective proposed generic versions of the FTSE 250 company's Suboxone sublingual film product to treat opioid addiction.
Lawsuits have been filed against Dr Reddy's, Actavis, Par, Alvogen and Teva alleging that they infringe patent number 9,855,221, which relates to certain polymer film compositions that have a "substantially uniform distribution of active drug". The patent was issued on 2 January 2018 and is listed in the Food & Drug Administration's Orange Book of approved drugs.
Last September, the company's tussle with generic competitors saw Indivior warn that a US court ruling over could lead to "material" loss of market share for Suboxone, a product that generates more than half of its revenues.
Later in the month, it filed new patent lawsuits against Dr Reddy's, Actavis, Par, Alvogen, Teva, and Mylan based on the June award of US patent 9,687,454 that was seen as protecting Suboxone film from generic competition. Indivior later struck an out-of-court settlement with Mylan over the issue.
On Thursday, Shaun Thaxter, Indivior's chief executive, said: "We continue to partner with Aquestive Therapeutics to innovate and generate new intellectual property around Suboxone film. We believe this new patent is strong and we are asserting it in order to protect our intellectual property rights."
Indivior will release its full year results on 15 February.
Lawsuits have been filed against Dr Reddy's, Actavis, Par, Alvogen and Teva alleging that they infringe patent number 9,855,221, which relates to certain polymer film compositions that have a "substantially uniform distribution of active drug". The patent was issued on 2 January 2018 and is listed in the Food & Drug Administration's Orange Book of approved drugs.
Last September, the company's tussle with generic competitors saw Indivior warn that a US court ruling over could lead to "material" loss of market share for Suboxone, a product that generates more than half of its revenues.
Later in the month, it filed new patent lawsuits against Dr Reddy's, Actavis, Par, Alvogen, Teva, and Mylan based on the June award of US patent 9,687,454 that was seen as protecting Suboxone film from generic competition. Indivior later struck an out-of-court settlement with Mylan over the issue.
On Thursday, Shaun Thaxter, Indivior's chief executive, said: "We continue to partner with Aquestive Therapeutics to innovate and generate new intellectual property around Suboxone film. We believe this new patent is strong and we are asserting it in order to protect our intellectual property rights."
Indivior will release its full year results on 15 February.
Related share prices |
---|
Indivior (INDV) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price